SITC Resource Library

Presentation slides and video from the 2025 Advances in Cancer Immunotherapy^™ (ACI) Series: A Focus on Bladder & Genitourinary Cancers were presented virtually on April 7, 2025.

Program Organizers

• Alan Tan, MD – Vanderbilt University Medical Center 
  
• Yuanquan (Aaron) Yang, MD, PhD – The Ohio State University
  
• Tian Zhang, MD, MHS – UT Southwestern Medical Center
  

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Program Learning Objectives

• Identify the cancer immunotherapy approaches in use for the treatment of bladder and genitourinary cancers.
• Summarize recent updates in cancer immunotherapy for bladder and genitourinary cancers including emerging toxicities and management.
• Implement cancer immunotherapy for bladder and genitourinary cancers into clinical practice appropriately.

You can view the program agenda here.

Please note on-demand recordings are not available for continuing education credits.